CorDynamics offers a variety of discovery models designed to investigate heart failure. These customized assessments leverage physiologically relevant paradigms with expert design and follow through to enable key lead optimization in drug discovery.

Our experience with these complicated heart failure models enable us to interrogate the effects of new compounds in multiple modes. We conduct investigations of heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF).

DRUG DISCOVERY – HFrEF & HFpEF

  • Isoproterenol induced diastolic dysfunction
  • Toxic cardiomyopathy
  • Transverse aortic constriction pressure overload
  • Post myocardial infarction remodeling
  • Dahl salt sensitive chronic hypertension
  • Obese and metabolic dysfunction
  • Tachypacing induced ventricular cardiomyopathy
  • Advanced conscious instrumented models
  • Chronic cardiac output and left ventricular function
  • Complex echocardiography assessments
  • Pressure-volume loop relationships